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Abstract  
BACKGROUND: The distinction between meningioma, schwannoma and solitary fibrous tumour/ 
hemangiopericytoma can be challenging in some cases. This study evaluates the expression of Somatostatin 
receptor 2A (SSTR2A) and Claudin-1 in these different tumours. 
MATERIAL AND METHODS: Thirty-five cases of meningioma, 10 cases of intracranial schwannoma and 10 
cases of hemangiopericytoma were assessed. The immunohistochemical expression of SSTR2A and Claudin-1 
was evaluated and scored according to the percentage of immunostained tumour cells (0: 1+, 2+ and 3). The 
intensity of staining was classified as weak, moderate and strong. 
RESULTS: Positivity for SSTR2A and Claudin-1 was encountered in 89% and 49% of meningiomas respectively. 
None of the schwannomas or hemangiopericytomas was positive for any of both markers. All grade I and II 
meningiomas were positive for SSTR2A, and only 20% of grade III showed positive staining (p < 0.05). Claudin-1 
positivity was detected in 50%, 43% and 60% of grade I, II and III meningioma respectively, with significantly 
higher intensity in grade III (p < 0.05). 
CONCLUSION: SSTR2A is highly sensitive and specific for meningioma. Claudin-1 is highly specific for 
meningioma, with low sensitivity. The adjunctive use of both markers can be very helpful in the diagnosis of 
meningioma and its distinction from schwannoma and hemangiopericytoma. 
 
 
 
 
Introduction 
 
Meningiomas are the most common primary 
central nervous system (CNS) tumours accounting for 
36% of all primary CNS tumours [1]. 
Since the first classification of meningioma 
introduced by Cushing in 1920 [2]; according to 
anatomical location; different classification schemes, 
adopted histology as the main factor in grading 
meningioma [3]. The recent WHO 2016 classification 
system, has grouped meningioma according to 
biological behavior into two groups, (1) 
Meningiomas with low risk of recurrence and 
aggressive behavior, including variants of WHO grade 
I meningiomas, and (2) Meningiomas with greater 
likelihood of recurrence and aggressive behavior, 
including variants of WHO grade II and grade III 
meningiomas and any subtype with high proliferation 
index, defined in one study as > 20 mitosis /10 HPF 
[4]. 
Both schwannomas of the cranio/spinal axis 
and meningeal Solitary fibrous tumour/ 
Hemangiopericytoma occur at a much lower 
frequency than meningioma. However, the 
distinction between these entities and meningioma 
can be challenging in some cases. Additional 
immunohistochemical studies are needed to resolve 
such cases [3]. The traditionally used 
immunohistochemical markers show some overlap in 
the expression between these entities [5][6][7]. 
Somatostatin receptors (SSTR) belong to a 
family of seven alpha-helical transmembrane 
spanning domains G protein-coupled receptors. They 
mediate the action of Somatostatin [8]. Somatostatin 
(SST) exerts inhibitory actions on some physiologic 
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processes including pituitary and pancreatic hormone 
secretion, gastrointestinal peptide secretion and 
motility. In the CNS, it plays a role as a 
neurotransmitter and neuromodulator affecting 
behaviour and cognition [9]. Finally, SST has a 
potent antiproliferative and antiangiogenic activity. 
Thus it can be used as an anti-neoplastic agent in 
tumours that express Somatostatin receptors [10][11]. 
The expression of somatostatin receptors is 
known to be frequent in meningioma [12]. There are 
five subtypes of somatostatin receptors (SSTR1-5). 
Among the five subtypes, SSTR2A was the most 
frequently detected in meningioma [8][13]. 
Claudin - 1 is one of the main components of 
tight junction, normally expressed in epithelial, 
endothelial and arachnoid cap cells, functioning as 
a regulator for paracellular space; controlling the 
barrier function of the cells and preserving cellular 
polarity and integrity [14]. 
Claudin - 1 has been recently identified as a 
tumor marker expressed in many tumors; e.g.: renal 
cell carcinoma, colonic adenocarcinoma and 
melanoma, where its increased expression and 
mislocalization were correlated with the bad behavior 
encountered in such tumors, e.g. metastatic potential 
[15]; through its inhibitory effect on E - cadherin and 
Beta-catenin inducing epithelial-mesenchymal 
transmission; a major step in metastatic process [16]. 
This study evaluates SSTR2A and Claudin-
1 immunohistochemical staining in meningiomas 
versus cranio - spinal schwannomas and meningeal 
solitary fibrous tumours/hemangiopericytomas, to 
determine if these two markers can help in this 
differential diagnosis and to add specific markers for 
meningioma that can be targeted therapeutically. 
 
 
Materials and Methods 
 
A total of 55 cases of CNS tumours were 
retrieved from the neuropathology files at Cairo 
University Hospital between 2012 and 2015. The 
ethics committee of Cairo University Hospital 
approved the study. The cases include 35 
meningiomas (22 females, 13 males), ten 
schwannomas (5 females, five males) and ten 
solitary fibrous tumours/hemangiopericytomas (6 
females, four males). The mean age of patients was 
42 years in cases of meningioma, 40 years in cases 
of schwannoma and 44 years in cases of solitary 
fibrous tumours/hemangiopericytoma. All cases were 
previously diagnosed by examination of Hematoxylin 
and Eosin stained sections and by routine 
immunohistochemical markers. 
Histological review: Five microns - thick 
tissue sections were cut from the archived paraffin 
blocks and stained by Hematoxylin and Eosin for 
histological re-evaluation according to the WHO 
criteria [3], the cases of meningioma are classified as 
grade I (n = 16), grade II (n = 14) and grade III (n = 
5). Among grade I meningiomas, five were 
transitional, four fibroblastic, three meningothelial, 
two psammomatous, one microcystic and one 
angiomatous. Grade II meningiomas included ten 
atypical and four chordoid and grade III 
meningiomas included three papillary and two 
rhabdoid variants. 
Immunohistochemical staining and 
evaluation: Additional cuts were prepared from the 
paraffin blocks, heat mediated antigen retrieval was 
performed (with low pH for SSTR2A and high pH 
for Claudin - 1) in automated water bath (Dako PT 
Link), and sections were stained with antibodies for 
SSTR2A (Abcam, UMB1, rabbit monoclonal, 1:100) 
and Claudin - 1 (Cell Marque, rabbit polyclonal, 
ready to use). Staining was performed in an 
autostainer (Dako autostainer link 48) using a 
polymer-based detection system (Dako EnVision 
FLEX
TM
K8000). 
Immunohistochemical staining for SSTR2A 
and Claudin - 1 was scored according to the 
percentage of immunostained tumour cells (0: less 
than 5%, 1+: 5% to 25%, 2+: 26% to 50%, 3+: more 
than 50%). The intensity of staining was classified as 
weak, moderate and strong. In claudin - 1 evaluation, 
the perineurial cells in peripheral nerves are used 
as a control for moderate intensity [14]. 
Statistical methods: Comparison of 
numerical variables between the study groups was 
done using Mann Whitney U test for independent 
samples. For comparing categorical data, Chi-square 
(X
2
) test was performed. The exact test was used 
instead when the expected frequency is less than 5. 
P values less than 0.05 was considered statistically 
significant. All statistical calculations were done 
using computer program SPSS (Statistical Package 
for the Social Science; SPSS Inc., Chicago, IL, USA) 
release 15 for Microsoft Windows (2006). 
 
 
Results 
 
Somatostatin receptor 2A 
Positive immunohistochemical staining for 
SSTR2A was encountered in 31 of 35 (89%) cases 
of meningioma (Table 1). All positive cases showed 
cytoplasmic and/or membranous staining. Among the 
positive cases, 24 of 31 (77%) showed diffuse 
staining in more than 50% of tumour cells (scored 
as 3+). Among these 24 cases, 16 showed strong 
immunostaining intensity, 7 showed moderate 
intensity, and only 1 showed weak staining (Figure 
1). 
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In contrast, none of the cases of 
schwannoma and solitary fibrous tumour/ 
hemangiopericytoma showed any positive staining 
for SST2A (Table 1). Therefore, the expression of 
SSTR2A was statistically significant in meningioma 
versus schwannoma or solitary fibrous tumours/ 
hemangiopericytoma (P <0.05) (Figure 2). 
Table 1: Summary of immunohistochemical staining results for 
meningioma, schwannoma and Solitary fibrous 
tumors/Hemangiopericytoma [number (percentage)] 
 Meningioma  
(n=35) 
Schwannoma  
(n = 10) 
Hemangiopericytoma  
(n = 10) 
SSTR2A positive 31 (89) 0 (0) 0 (0) 
Claudin-1 positive 17 (49) 0 (0) 0 (0) 
SSTR2A&/or Claudin - 1 
positive 
34 (97) 0 (0) 0 (0) 
 
 
SSTR2A, somatostatin receptor 2A 
Regarding the different grades of 
meningioma, a significant correlation was found 
between the positive expression of SSTR2A and the 
lower grades of meningioma (grades I and II) (P 
<0.05) (Table 2).  
Table 2: Summary of immunohistochemical staining results for 
different grades of meningioma [number (percentage)] 
 Grade I (n = 16) Grade II (n = 14) Grade III (n = 5) 
SSTR2A positive 16 (100) 14 (100) 1 (20) 
Claudin-1 positive 8 (50) 6 (43) 3 (60) 
 
In grade I, all cases (16/16) showed positive 
SSTR2A expression. Among these cases, 13 showed 
diffuse staining in more than 50% of tumour cells 
(Score 3+). The majority of these cases displayed 
strong immunostaining intensity. In grade II, all cases 
(14/14) showed positive SSTR2A expression. 10 out 
of these 14 cases showed diffuse staining in more 
than 50 % of cells (Score 3+), but only 4 of them 
showed strong intensity. In grade III, only a single 
(1/5) case of papillary subtype showed positive 
SSTR2A expression. The staining, in this case, 
was diffuse in more than 50% of tumour cells (Score 
3+); however, the intensity was weak. 
 
Figure 1: Transitional meningioma, WHO grade I (A: H&E, x400) 
showing strong diffuse SSTR2A immunostaining (B: SSTR2A, 
x400). Rhabdoid meningioma, WHO grade III (C: H&E, x200) 
showing strong diffuse Claudin - 1 immunostaining (D: Claudin-1, 
x200) immunostaining of claudin 1 (D: claudin 1x400) 
Claudin-1 
Positive immunohistochemical staining was 
encountered in 17 of 35 (49%) cases of 
meningioma. Tumor cells showed cytoplasmic 
and/or membranous staining. Unlike SSTR2A, 
Claudin - 1 showed only focal staining in less than 
50% of tumour cells in all positive cases (Figure 1).  
 
Figure 2: Hemangiopericytoma (A: H&E, x400) showing negative 
immunostaining for SSTR2A (B: SSTR2A, x400). Schwannoma (C: 
H&E, x400) showing negative 
 
However, a significant expression of Claudin 
- 1 was still detected in meningioma in comparison to 
schwannoma and solitary fibrous tumour/ 
hemangiopericytoma (P< 0.05) since none of them 
showed any positive staining (Table 1) (Figure 2). 
Table 3: Intensity of immunohistochemical staining of Claudin-
1 in different grades of meningioma [number (percentage)] 
 Grade I (n=16) Grade II (n=14) Grade III (n=5) 
Negative 8 (50) 8 (57) 2 (40)
 
Weak 2 (13) 3 (21.5) 0 (0)
 
Moderate 5 (31) 3 (21.5) 0 (0)
 
Strong 1 (6) 0 (0) 3 (60)
 
 
As for the three grades of meningioma, 
positive Claudin - 1 expression was detected in 8 out 
of 16 grade I cases, 6 out of 14 grade II cases 
and 3 out of 5 grade III cases. The intensity of 
Claudin - 1 staining was significantly stronger in 
grade III than in grades I and II (P <0.05) (Table 3). 
Interestingly, the three positive cases of grade III 
were negative for SSTR2A. More details of SSTR2A 
and Claudin - 1 staining in different grades and 
subtypes of meningioma are shown in (Table 4). 
 
 
Discussion 
 
Although the diagnosis of most 
meningiomas can be based merely on routine 
examination of Hematoxylin and Eosin stained 
sections, the histologic mimicry between certain 
subtypes and other CNS tumours warrants the use 
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of immunohistochemical tests. A common example is 
a distinction between meningioma, particularly the 
fibroblastic subtypes, and schwannoma, especially if 
arising at the cerebello - pontine angle.  
Table 4: Details of immunohistochemical staining of SSTR2A 
and Claudin - 1 in all cases of meningioma 
Case  Grade Subtype  SSTR2A  Claudin-1 
1 I  Transitional 3+ Strong 1+ Moderate 
2 I  Transitional 3+ Strong 1+ Moderate 
3 I  Transitional 3+ Strong 1+ Moderate 
4 I  Transitional 3+ Moderate 0 0 
5 I  Transitional 1+ Weak 0 0 
6 I  Fibroblastic 3+ Strong 2+ Moderate 
7 I  Fibroblastic 3+ Strong 0 0 
8 I  Fibroblastic 3+ Strong 0 0 
9 I  Fibroblastic 3+ Strong 0 0 
10 I  Meningothelial 3+ Strong 1+ Weak 
11 I  Meningothelial 2+ Moderate 2+ Moderate 
12 I  Meningothelial 2+ Moderate 0 0 
13 I  Psammomatous 3+ Strong 2+ Strong 
14 I  Psammomatous 3+ Strong 0 0 
15 I  Microscystic 3+ Strong 0 0 
16 I  Angiomatous 3+ Strong 1+ Weak 
17 II  Chordoid 3+ Moderate 1+ Weak 
18 II  Chordoid 3+ Moderate 1+ Weak 
19 II  Chordoid 3+ Moderate 0 0 
20 II  Chordoid 2+ Moderate 0 0 
21 II  Atypical 3+ Strong 1+ Moderate 
22 II  Atypical 3+ Strong 1+ Weak 
23 II  Atypical 3+ Strong 0 0 
24 II  Atypical 3+ Strong 0 0 
25 II  Atypical 3+ Moderate 1+ Moderate 
26 II  Atypical 3+ Moderate 0 0 
27 II Atypical 3+ Moderate 0 0 
28 II Atypical 2+ Moderate 0 0 
29 II Atypical 2+ Weak 2+ Moderate 
30 II Atypical 1+ Weak 0 0 
31 III Papillary 3+ Weak 0 0 
32 III Papillary 0 0 1+ Strong 
33 III Papillary 0 0 0 0 
34 III Rhabdoid 0 0 2+ Strong 
35 III Rhabdoid 0 0 1+ Strong 
 
This differential diagnosis should also be 
considered in patients diagnosed with 
Neurofibromatosis type 2 since these patients are 
prone to develop both tumours. Histologically, 
fibroblastic meningioma and schwannoma are 
formed of spindle cells with the variable collagenous 
background. Occasionally, well-formed whorls that 
are characteristic for meningioma are seen in 
schwannoma. On the other side, meningioma can 
show Verocay body - like structures similar to those 
seen in schwannoma. Although most meningiomas 
express epithelial membrane antigen (EMA), a small 
subset of cases does not. Also, S100 - which is 
routinely used for diagnosis of schwannoma- can stain 
up to 70% of fibroblastic meningiomas [5]. 
Another problematic case is the differential 
diagnosis of meningioma versus solitary fibrous 
tumour/hemangiopericytoma. Some meningiomas 
develop branching staghorn vessels like those 
encountered in solitary fibrous tumour/ 
hemangiopericytoma [5]. Previous studies had shown 
that occasional cases of solitary fibrous tumour/ 
hemangiopericytoma might focally express EMA [7]. 
Also, CD34, which is a marker of solitary fibrous 
tumour/hemangiopericytoma, can be expressed in up 
to 60% of fibroblastic meningiomas [6]. 
In the present study, we compared the 
immunohistochemical expression of SSTR2A and 
Claudin - 1 in meningioma versus their expression in 
schwannoma and solitary fibrous tumour/ 
hemangiopericytoma. 
The expression of somatostatin receptors is 
known to be frequent in meningioma [12]. Among 
the five subtypes of somatostatin receptors, SSTR2A 
was the most frequently detected in meningioma 
[13]. This wide expression has made it a useful 
tool in tumour imaging by PET/CT using radiolabeled 
somatostatin analogues [17]. 
In our study, we detected the 
immunohistochemical expression of SSTR2A in 
meningiomas with a sensitivity of 89%. This is 
comparable with the findings detected by Bacchi et 
al. [18], Agaimy et al. [19] and Menke et al. [20] 
in their studies that showed sensitivities of 100%, 
87% and 100 % respectively. Lower sensitivities of 
74% and 63% were stated by Barresi et al. [21] and 
Durand et al. [22] respectively. This difference may 
be because they used polyclonal antibodies in their 
studies, in contrast to the monoclonal antibody used 
in the current study. 
We further analysed the expression of 
SSTR2A in different grades and subtypes of 
meningioma. The highest expression was linked to 
lower grades of meningioma (grade I and II) (p < 
0.05). It was also noted that despite the positive 
expression of SSTR2A in all cases of grade I and II, 
there was still a difference in the intensity of 
immunostaining among the grades. Most of the 
cases of grade I (75%) showed strong staining 
intensity while only 28% of grade II cases showed 
strong intensity and the rest showed moderate or 
weak intensity. As for grade III meningiomas, only 
one case was positive for SSTR2A, and the 
intensity of staining was weak. 
Our findings are in concordance with those 
reported by Durand et al. [22] who analysed the 
expression of SSTR2A in meningiomas by both 
immunohistochemistry and RT - PCR. By 
immunohistochemistry, the expression of SSTR2A 
was negative in grade III meningiomas. By RT - 
PCR, the SSTR2A mRNA was detected in all 
grades of meningioma with higher levels expressed 
in grade I more than in grade II and III. 
Since the expression of SSTR2A was more 
intense in grade I meningiomas and became lost in 
most of grade III cases, we suggest that detection 
of strong immunohistochemical staining of SSTR2A 
may predict a better outcome. Previous studies 
were done on other types of tumours also reached 
the same conclusion. For example, Sestini et al. [23] 
and Raggi et al. [24] studied SSTR2A expression in 
neuroblastoma and found out that it was inversely 
related to the tumour stage and was shown to be a 
good independent prognostic factor. Similarly, in 
colorectal carcinoma, SSTR2A expression was 
increased in well and moderately differentiated 
tumours and with lower proliferation indices [25]. 
In all cases of schwannoma and solitary 
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fibrous tumor/hemangiopericytoma selected for the 
present study, SSTR2A showed negative staining. 
Accordingly, the specificity of SSTR2A for 
meningioma is 100%. This was statistically highly 
significant. Bacchi et al. [18] and Menke et al. [20] 
reported slightly lower specificities of 90% and 88% 
respectively. 
Regarding Claudin - 1, its sensitivity for 
meningioma was 49% in our study. The previous 
study done by Rajaram et al. [7] included anaplastic 
(grade III) meningiomas only and showed a 
sensitivity of 54%. Hahn et al. [14] included grade 
I and II meningiomas and showed a sensitivity of 53 
%, which is relatively close to our results. Slightly 
lower sensitivity (22%) was reported by Soini et al. 
[26] who included all grades of meningioma. This 
difference may be because they used tissue micro- 
array blocks with a 2 mm diameter. 
Despite its low sensitivity for meningiomas, 
Claudin - 1 did not stain any of the schwannomas or 
solitary fibrous tumours/ hemangiopericytomas 
included in our study, denoting a very high 
specificity (100%) for meningioma. Similar to our 
results, Singh et al. [27] reported negative Claudin-1 
staining in the 50 cases of schwannoma included in 
their study. Hahn et al. [14] also reported negative 
Claudin - 1 staining in all the studied cases of 
meningeal solitary fibrous tumour/ 
hemangiopericytoma and schwannoma. Rajaram et 
al. [7] studied Claudin - 1 expression in 15 cases of 
meningeal solitary fibrous tumour/ 
hemangiopericytoma and found positive staining in 2 
cases. 
We detected positive expression of 
Claudin - 1 in the different grades of meningioma 
without a significant difference in positivity (50% of 
grade I, 43% of grade II and 60% of grade III). Soini 
et al. [26] also reported no difference in the Claudin - 
1 expression among the three grades of meningioma. 
However, we detected that the intensity of staining 
was significantly higher in grade III than in grades I 
and II (p > 0.05). 
In the current study, we found out that 34 of 
35 meningiomas expressed either SSTR2A or Claudin 
- 1, or both of them, i.e. the sensitivity of both 
markers combined is 97%. Interestingly, the cases 
of grade III meningiomas that showed positive 
Claudin - 1 staining was negative for SSTR2A. On 
the other side, the single case of grade III 
meningioma (papillary subtype) that was positive for 
SSTR2A did not stain for Claudin - 1. Thus SSTR2A 
and Claudin - 1 can be used as complimentary 
markers with high sensitivity. 
Therapeutic strategies in meningiomas 
include mainly surgery and radiotherapy, while 
chemotherapy has been used for a patient with the 
progressive disease, and patients with histologically 
malignant meningioma as an adjuvant for 
radiotherapy, however, the response to 
chemotherapy was disappointing; so the targeted 
therapy in such cases can be a new hope [28]. In 
vitro studies proved that somatostatin analogues have 
a cytostatic effect on tumor cells and inhibits the 
tumor growth [10][29]. However, the efficacy of the 
use of somatostatin analogues in a clinical setting is 
still debatable with some trials showing benefit for 
their use and others do not [30][31][32]. The loss of 
expression of SSTR2A in malignant meningioma, as 
shown in the present study, may explain the failure 
of some clinical trials to prove the efficacy of 
somatostatin analogues in treating recurrent high-
grade meningioma [33]. 
Recently, Hashimoto and his colleagues 
generated mouse anti - Claudin-1 monoclonal 
antibodies and assessed their activity on mice 
bearing human Claudin - 1 expressing tumours. They 
concluded that one of these antibodies might be of 
benefit in cancer therapy [34]. So Claudin - 1 can be 
one of the targeted therapy lines in meningioma 
therapy. 
In summary, our study demonstrates that 
SSTR2A is highly sensitive and specific for 
meningioma. Claudin - 1 is highly specific for 
meningioma; however its sensitivity is low. The 
adjunctive use of both markers can be very helpful 
in the diagnosis of meningioma and its distinction 
from schwannoma and solitary fibrous tumor/ 
hemangiopericytoma. Further clinicopathological 
studies are recommended to correlate the pattern 
of SSTR2A and Claudin - 1 expression in 
meningiomas with their potential prognostic and 
predictive roles in such tumors, specifically 
aggressive and recurring ones. 
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